BELLUS Health Inc. (BLU)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BELLUS Health Inc. (BLU) trades at $14.74 with AI Score 48/100 (Grade C). BELLUS Health Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cough hypersensitivity. Market cap: $1.87B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BLU: BLU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BLU against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BLU: the 1 perspectives are evenly split.
How is this calculated? →BELLUS Health Inc. (BLU) Healthcare & Pipeline Overview
BELLUS Health Inc. is a clinical-stage biopharmaceutical firm developing BLU-5937, a P2X3 receptor antagonist, for refractory chronic cough (RCC) and chronic pruritus. The company operates in the competitive biotechnology sector, focusing on addressing unmet needs in cough hypersensitivity disorders.
What Is the Investment Thesis for BLU?
BELLUS Health Inc. presents a focused investment opportunity within the biotechnology sector, centered on its lead product candidate, BLU-5937. The potential success of BLU-5937 in treating refractory chronic cough (RCC) and chronic pruritus is a key value driver. Positive Phase II clinical trial results could significantly increase the company's market capitalization. However, the company's negative profit margin of -475500.0% and gross margin of -21967104.1% highlight the risks associated with clinical-stage companies. Upcoming Phase II trial results for BLU-5937 will be a critical catalyst. Investors should carefully consider the clinical trial outcomes and competitive landscape before investing.
Based on FMP financials and quantitative analysis
BLU Key Highlights
- Market capitalization of $1.87B reflects investor expectations for BLU-5937.
- P/E ratio of -22.36 indicates the company is currently unprofitable, typical for clinical-stage biopharmaceutical companies.
- Negative profit margin of -475500.0% underscores the significant R&D expenses associated with drug development.
- Gross margin of -21967104.1% reflects the lack of product revenue as the company is still in the clinical stage.
- Beta of -0.28 suggests the stock is less volatile than the overall market.
Who Are BLU's Competitors?
BLU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMAM Ambrx Biopharma Inc. | $28.00 | +0.07% | $1.77B | 51 |
| ASTH Astrana Health, Inc. | $47.56 | -3.27% | $2.36B | 86 |
| CALT Calliditas Therapeutics AB (publ) | $40.00 | -0.10% | $2.15B | 46 |
| CINC CinCor Pharma, Inc. | $29.06 | +0.00% | $1.27B | 47 |
| CTIC CTI BioPharma Corp. | $9.10 | +0.06% | $1.20B | 56 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BLU's Key Strengths?
- Novel P2X3 receptor antagonist mechanism.
- Focus on unmet needs in cough hypersensitivity.
- Phase II clinical trial progress for BLU-5937.
- Experienced management team.
What Are BLU's Weaknesses?
- Clinical-stage company with no product revenue.
- High R&D expenses and negative profitability.
- Reliance on successful clinical trial outcomes.
- Competition from established pharmaceutical companies.
What Could Drive BLU Stock Higher?
- Announcement of Phase II clinical trial results for BLU-5937 in RCC.
- Enrollment and progress in ongoing clinical trials.
- Potential for strategic partnerships or collaborations.
What Are the Key Risks for BLU?
- Financial-distress signal — its Altman Z-Score of 1.37 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-22.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other cough therapies.
- Patent challenges or loss of exclusivity.
What Are the Growth Opportunities for BLU?
- Expansion into new indications: BELLUS Health can explore the potential of BLU-5937 in treating other cough hypersensitivity indications beyond RCC and chronic pruritus. This could significantly expand the addressable market and increase revenue potential. The timeline for this expansion depends on the results of ongoing and future clinical trials. The market size for related indications could be substantial, potentially reaching hundreds of millions of dollars.
- Partnerships and collaborations: BELLUS Health can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of BLU-5937. This could provide access to additional funding, expertise, and resources. The timeline for securing partnerships is uncertain, but it could occur within the next 1-2 years. Successful partnerships could significantly de-risk the development program and enhance the company's value.
- Geographic expansion: BELLUS Health can expand its geographic reach beyond North America to target markets in Europe and Asia. This could increase the patient population and revenue potential. The timeline for geographic expansion depends on regulatory approvals and market access strategies. The market size in these regions could be significant, potentially exceeding hundreds of millions of dollars.
- Advancement of pipeline: BELLUS Health can invest in research and development to advance its pipeline of preclinical and early-stage assets. This could provide new growth opportunities and diversify the company's product portfolio. The timeline for advancing the pipeline depends on the success of preclinical studies and early-stage clinical trials. The potential market size for new products is uncertain but could be substantial.
- Acquisition of complementary assets: BELLUS Health can acquire complementary assets or technologies to strengthen its position in the cough hypersensitivity market. This could provide access to new products, expertise, and resources. The timeline for acquisitions is uncertain, but it could occur within the next 2-3 years. Successful acquisitions could enhance the company's competitive advantage and drive long-term growth.
What Opportunities Does BLU Have?
- Expansion into new indications for BLU-5937.
- Strategic partnerships for development and commercialization.
- Geographic expansion to new markets.
- Advancement of pipeline assets.
What Threats Does BLU Face?
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other cough therapies.
- Patent challenges or loss of exclusivity.
What Are BLU's Competitive Advantages?
- Proprietary P2X3 receptor antagonist technology.
- Clinical trial data supporting BLU-5937 efficacy.
- Patent protection for BLU-5937.
- Expertise in cough hypersensitivity research.
What Does BLU Do?
BELLUS Health Inc., founded in 1993 and headquartered in Laval, Canada, is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cough hypersensitivity and related conditions. The company's primary focus is on refractory chronic cough (RCC) and chronic pruritus, areas with significant unmet medical needs. Their lead product candidate, BLU-5937, is an antagonist of the P2X3 receptor, a key mediator in cough and itch signaling pathways. BLU-5937 is currently undergoing Phase II clinical trials for the treatment of RCC. BELLUS Health is committed to improving the lives of patients suffering from these debilitating conditions through innovative research and development. The company's strategy involves advancing BLU-5937 through clinical development and exploring potential partnerships to maximize its commercial potential. BELLUS Health operates primarily in North America, with a focus on the United States and Canada.
What Products and Services Does BLU Offer?
- Develop therapeutics for refractory chronic cough (RCC).
- Focus on cough hypersensitivity indications.
- Develop BLU-5937, a P2X3 receptor antagonist.
- Conduct Phase II clinical trials for BLU-5937 in RCC.
- Research treatments for chronic pruritus.
- Target unmet medical needs in cough and itch.
How Does BLU Make Money?
- Develop and commercialize novel therapeutics.
- Focus on P2X3 receptor antagonism.
- Out-license or partner for commercialization.
- Generate revenue through product sales or royalties.
What Industry Does BLU Operate In?
BELLUS Health operates within the biotechnology industry, which is characterized by high risk and high reward. The company focuses on cough hypersensitivity, a niche area within respiratory diseases. The market for chronic cough treatments is growing, driven by an aging population and increasing awareness of the condition. Competition includes companies developing similar P2X3 receptor antagonists and other cough therapies. Success in this industry depends on clinical trial outcomes, regulatory approvals, and commercialization strategies. The biotechnology sector is subject to intense regulatory scrutiny and patent challenges.
Who Are BLU's Key Customers?
- Patients with refractory chronic cough (RCC).
- Patients with chronic pruritus.
- Healthcare providers treating cough and itch.
- Pharmaceutical companies (potential partners).
F-Score 3/9Financial Health
BELLUS Health Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.37 places it in the distress zone, a signal of elevated financial risk.
BLU Valuation & Market Position
With a $1.87B market cap, BELLUS Health Inc. sits in the small-cap segment of the market. Relative to its peer group, BLU's quantitative score of 48/100 is roughly in line with the peer average of 57/100.
ROE -22%Key Financial Metrics
Return on equity for BELLUS Health Inc. stands at -22.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 22.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.8%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
BELLUS Health Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Laval, CA. The company is led by CEO Roberto Francesco Bellini. BLU has traded publicly since 2000.
BLU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel P2X3 receptor antagonist mechanism.
- Focus on unmet needs in cough hypersensitivity.
- Phase II clinical trial progress for BLU-5937.
- Experienced management team.
Bear Case
- Clinical-stage company with no product revenue.
- High R&D expenses and negative profitability.
- Reliance on successful clinical trial outcomes.
- Competition from established pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BLU Latest News
-
Blue Owl Technology Finance: Buying The Fear In The Right Place
All Articles on Seeking Alpha · Jun 12, 2026
BLU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BLU.
Price Targets
Wall Street price target analysis for BLU.
BLU MoonshotScore
What does this score mean?
The MoonshotScore rates BLU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Roberto Francesco Bellini
CEO
Roberto Bellini has extensive experience in the pharmaceutical and biotechnology industries. Prior to joining BELLUS Health, he held leadership positions at Picchio Pharma Inc. and Dompé International SA, where he focused on business development and strategic planning. His background includes a strong track record in building and managing successful pharmaceutical companies. He is responsible for overseeing the overall strategy and operations of BELLUS Health.
Track Record: Under Roberto Bellini's leadership, BELLUS Health has advanced BLU-5937 through Phase II clinical trials. He has also overseen the company's financing activities and strategic partnerships. Key milestones include the initiation and completion of clinical trials, as well as securing funding to support the company's research and development programs. He is focused on driving the company's growth and creating value for shareholders.
What Investors Ask About BELLUS Health Inc. (BLU) — Healthcare
What does BELLUS Health Inc. do?
BELLUS Health Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cough hypersensitivity. Their lead product candidate, BLU-5937, is a P2X3 receptor antagonist being developed for the treatment of refractory chronic cough (RCC) and chronic pruritus. The company aims to address unmet medical needs in these areas through innovative research and development, with the goal of improving the lives of patients suffering from these debilitating conditions. The company is currently focused on advancing BLU-5937 through clinical trials and exploring potential partnerships to maximize its commercial potential.
What are the main risks for BLU?
The main risks for BELLUS Health Inc. include the potential for clinical trial failures or delays, which could significantly impact the company's value. Regulatory hurdles and approval delays also pose a risk, as they could delay or prevent the commercialization of BLU-5937. Competition from other cough therapies and patent challenges or loss of exclusivity could also negatively impact the company's market position. Additionally, the company's reliance on successful clinical trial outcomes and its high R&D expenses create financial risks.
What are the key factors to evaluate for BLU?
BELLUS Health Inc. (BLU) holds an AI score of 48/100 (low). Not financial advice.
How frequently does BLU data refresh on this page?
BLU prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BLU's recent stock price performance?
BELLUS Health Inc. (BLU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel P2X3 receptor antagonist mechanism. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BLU overvalued or undervalued right now?
Valuing BELLUS Health Inc. (BLU) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BLU?
Before investing in BELLUS Health Inc. (BLU), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BLU to a portfolio?
Key strength of BELLUS Health Inc. (BLU): Novel P2X3 receptor antagonist mechanism. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.